Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Triple‐class‐refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low‐dose dexamethasone (Sel‐dex) demonstrated a 26.2% overall response rate in...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Jagannath, Sundar, Chari, Ajai, Vogl, Dan T., Dimopoulos, Meletios A., Moreau, Philippe, Dingli, David, Wei, Lee‐Jen, Richter, Joshua, Biran, Noa, Siegel, David, Reichmann, William, Li, Lingling, Tang, Shijie, Saint‐Martin, Jean‐Richard, Joshi, Anita, Kauffman, Michael, Shah, Jatin, Shacham, Sharon, Lonial, Sagar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy–Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175889/
https://www.ncbi.nlm.nih.gov/pubmed/35846096
http://dx.doi.org/10.1002/jha2.120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175889/
https://www.ncbi.nlm.nih.gov/pubmed/35846096
http://dx.doi.org/10.1002/jha2.120

Ejemplares similares